文献速递神经肿瘤

胶质瘤患者无进展生存期内健康相关生活质量下降的相关因素

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
PubMed 文献 · Neuro Oncol · 2022-01-01

结果显示,至疾病进展前,各评估量表上有9-29%的患者出现HRQoL下降,同时考虑所有量表时47%的患者在至少1个量表上下降;无进展期内仅较差体能状态与大多数量表的临床相关HRQoL下降独立相关,治疗与HRQoL下降无独立关联。

要点

  • 无进展生存期内仅53%的患者HRQoL得以维持。
  • 同时考虑所有量表时47%的患者在至少1个量表上出现HRQoL下降。
  • 大多数量表上仅较差体能状态与无进展期HRQoL下降独立相关,治疗无独立关联。

核心结论

  • 无进展生存期内仅53%的患者HRQoL得以维持,且治疗与HRQoL下降无独立关联。
  • 因此在整个疾病过程中常规监测患者的功能与健康状态很重要,以便在出现问题信号时启动干预。

研究设计与样本

  • 按量表及个体患者水平(同时考虑所有量表)确定HRQoL稳定至进展的患者百分比。
  • 评估至临床相关HRQoL下降的时间,以无下降生存期和至下降时间表示(前者将进展作为事件)。
  • 分析社会人口学与临床因素与无进展期HRQoL下降的关联。

主要发现

  • 患者从随机化至进展的中位时间为7.6个月。
  • 在评估的HRQoL量表上,9-29%的患者在疾病进展前出现下降。
  • 同时考虑所有量表时,47%的患者在至少1个量表上出现下降。
  • 中位无下降生存期为3.8-5.4个月,中位至下降时间为8.2-11.9个月。
  • 在大多数量表上,仅较差体能状态与无进展期临床相关HRQoL下降独立相关。

临床怎么用

  • 作者认为,在整个疾病过程中常规监测患者的功能与健康状态很重要,以便在出现问题信号时启动干预。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period. METHODS: We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period. RESULTS: Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9-29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on ≥1 scale. Median deterioration-free survival period ranged between 3.8-5.4 months, and median time-to-deterioration between 8.2-11.9 months. For most scales, only poor performance status was independently associated with clinically relevant HRQoL deterioration in the progression-free period. CONCLUSIONS: HRQoL was maintained in only 53% of patients in their progression-free period, and treatment was not independently associated with this deterioration in HRQoL. Routine monitoring of the patients' functioning and well-being during the entire disease course is therefore important, so that interventions can be initiated when problems are signaled.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Coomans MB, Dirven L, Aaronson N, et al. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro Oncol. 2022. PMID: 35404443. doi:10.1093/neuonc/noac097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。